#Blue spark Patch#

For more information, please visit follow us About Blue Spark Technologies Use of Carevive in the clinic unlocks critical data on the real-world experience of patients with cancer, to continuously improve patient care today and advance cancer drug development. Our platform enables clinicians to monitor and manage their patients remotely, which improves clinical outcomes and patient quality of life. founded in 2013, is an oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. “The TempTraq and Carevive project has the potential to lay a strong foundation for the design of a larger study looking at remote patient monitoring in the oncology setting.” About Carevive SystemsĬarevive Systems, Inc. “The use of a symptom monitoring and high frequency temperature dataset can allow for targeted triage and efficient clinical decision making with the goal of early intervention,” said Sung Choi, M.D., Associate Professor of Pediatric Hematology/Oncology at the University of Michigan and Lead Investigator on the pilot study. “Our team has created a soft, comfortable patch, and we’re delighted to be able to use it to support this revolutionary approach to improving cancer care.” “TempTraq has been clinically proven to detect fevers hours before the standard of care in high-risk chemotherapy treatments, bone marrow transplants and CAR-T’s, and those hours are critical in this patient population,” said Ruth Phillips, Director of Medical Affairs at Blue Spark Technologies. The opportunity to learn from clinicians about these data value and patients about their reporting experience are key pilot goals.

#Blue spark Patch#

Patients in the study will report their symptoms through Carevive’s PROmpt® while wearing Blue Spark’s TempTraq®, a soft wearable patch that continuously, safely and comfortably monitors body temperature, allowing clinicians to also monitor real-time patient health data. Often the first sign of infection is an increase in body temperature (fever). Cancer and chemotherapy can reduce the effectiveness of the immune system by reducing the number of infection-fighting white blood cells. We’re really excited by the potential outcomes of this study to help countless more cancer patients.”Īccording to the Centers for Disease Control and Prevention (CDC), people with cancer who are treated with chemotherapy are more likely to develop infections. “Electronic patient-reported outcomes data are crucial for proactive symptom management – helping patients live more comfortably, and for longer, while studying them together provides us with an important resource for improving patient-centered care. Clinical Content Developer, Carevive Systems, Inc.

“We’re proud to be putting patients’ real-world experiences at the heart of the care process,” said April Boyd, Sr.